Known targets — ChEMBL curated mechanism
CDK2CDK4CDK6CHEK1PDPK1PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3
The experimentally established mechanism targets of Ucn-01. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ known ✓ | Q04759 | 14/20 | 1.00 |
| ▸ | PRKCD known ✓ | Q05655 | 13/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 12/20 | 1.00 |
| ▸ | PRKCG known ✓ | P05129 | 12/20 | 1.00 |
| ▸ | PRKCZ known ✓ | Q05513 | 12/20 | 1.00 |
| ▸ | PRKCE known ✓ | Q02156 | 12/20 | 1.00 |
| ▸ | PRKCB known ✓ | P05771 | 11/20 | 1.00 |
| ▸ | PRKCA known ✓ | P17252 | 11/20 | 1.00 |
| ▸ | PRKCH known ✓ | P24723 | 11/20 | 1.00 |
| ▸ | PRKCI known ✓ | P41743 | 11/20 | 1.00 |
| ▸ | PRKD1 known ✓ | Q15139 | 11/20 | 1.00 |
| ▸ | CHEK1 known ✓ | O14757 | 5/20 | 1.00 |
| ▸ | CDK2 known ✓ | P24941 | 3/20 | 1.00 |
| ▸ | PDPK1 known ✓ | O15530 | 3/20 | 0.73 |
| ▸ | CDK4 known ✓ | P11802 | 2/20 | 0.73 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.73 |
| ▸ | PRKACA | P17612 | 9/20 | 1.00 |
| ▸ | PRKACG | P22612 | 8/20 | 1.00 |
| ▸ | PRKACB | P22694 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ucn-01 SCHEMBL29354706 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL14217901 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL14190736 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL17470230 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13169435 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL259162 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL24105650 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13170168 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL20068300 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13933132 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125401-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | PERCIPIAD, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12479866-B2 | Boron-containing rho kinase inhibitors | PERCIPIAD, INC. | 2025-11-25 | — | — | US | disclosed |
| EP-3999072-B1 | BORON-CONTAINING RHO KINASE INHIBITORS | PERCIPIAD INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| WO-2024028476-A1 | METHODS FOR THE TREATMENT OF TH2-MEDIATED DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-02-08 | — | — | WO | disclosed |
| US-20220389035-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | PERCIPIAD, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3056210-B1 | DRUG FOR PREVENTION OR TREATMENT OF SPINOCEREBELLAR DEGENERATION | UNIV NAT CORP TOKYO MEDICAL & DENTAL (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20220061311-A1 | COMPOSITIONS AND METHODS FOR REDUCING CRYOPRESERVATION TOXICITY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-03-03 | — | — | US | disclosed |
| US-10989719-B2 | Methods for treating spinocerebellar ataxia type I using RPA1 | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10940188-B2 | Compounds and methods for treatment and prevention of Flavivirus infection | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-7132440-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-07 | — | — | US | disclosed |
| WO-2006004791-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1613313-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-11 | — | — | EP | disclosed |
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-01-05 | — | — | US | disclosed |
| CN-1582150-A | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | NOVARTIS AG (CH) | 2005-02-16 | — | — | CN | disclosed |
| WO-2004093873-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-`4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214857-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-10-28 | — | — | US | disclosed |
| EP-1435947-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHOMCNEIL PHARMACEUTICAL, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003032984-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDSI/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | WEE1, CDKN1A, DDB1 | PRKCQ 4825/4885PRKCD 4224/4885PRKD3 1898/4885 |
| US-10940188-B2 | Compounds and methods for treatment and prevention of Flavivirus infection | CDK2, CDKN1A, PSENEN | PRKCQ 3237/4885PRKCD 2950/4885PRKD3 3309/4885 |
| US-20220389035-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOT2 | PRKCQ 82/4885PRKCD 615/4885PRKD3 390/4885 |
| US-20220061311-A1 | COMPOSITIONS AND METHODS FOR REDUCING CRYOPRESERVATION TOXICITY | IQGAP1, UGGT1, FLNA | PRKCQ 431/4885PRKCD 1478/4885PRKD3 487/4885 |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, TMBIM6, CDS2 | PRKCQ 4588/4885PRKCD 4025/4885PRKD3 2199/4885 |
| US-20260125401-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | NTRK2, GRK6, GRK1 | PRKCQ 126/4885PRKCD 257/4885PRKD3 253/4885 |
| US-12479866-B2 | Boron-containing rho kinase inhibitors | ROCK1, ROCK2, RHOT2 | PRKCQ 82/4885PRKCD 615/4885PRKD3 390/4885 |
| US-20040214857-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, CDS2, DDB1 | PRKCQ 4675/4885PRKCD 4142/4885PRKD3 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.